Adenoid Cystic Carcinoma Clinical Trial
— LUPSAOfficial title:
Lutetium-177-PSMA Radioligand Therapy for Advanced Salivary Gland Cancer, a Phase II Pilot Study.
Verified date | May 2023 |
Source | Radboud University Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Phase 2 pilot study, which evaluates the safety and efficacy of Lutetium-177-PSMA radioligand therapy in advanced salivary gland cancer patients.
Status | Completed |
Enrollment | 12 |
Est. completion date | February 13, 2023 |
Est. primary completion date | February 13, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients must have the ability to provide written informed consent. - Patients must be = 18 years of age. - Patients must have an ECOG performance status of 0 to 2. - Patients must have histological, pathological, and/or cytological confirmation of either adenoid cystic carcinoma or salivary duct carcinoma. - Patients must have incurable, local or regional recurrent or metastatic ACC or SDC. - Patients with ACC can only participate in case of objective growth in the last three months or complaints due to the disease. - Patients must have adequate organ function: - Sufficient bone marrow capacity as defined by: WBC count (white blood cell) =2.5x10^9/L, PLT (platelet) count =100x10^9/L, Hb =6 mmol/L, absolute neutrophil count (ANC) =1.5x10^9/L - Adequate liver function as defined by:Total bilirubin =1.5 x ULN. For patients known with Gilbert's Syndrome = 3 x ULN is permitted. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =3.0 × ULN OR =5.0 × ULN for patients with liver metastases. - Adequate kidney function as defined by:serum creatinine =1.5 x ULN or creatinine clearance = 50 mL/min - Patients must have measurable disease at baseline. Defined as = 1 lesion = 2 cm (long axis) that is present on baseline CT. - Patients must have a positive 68Ga-PSMA PET/CT scan, defined by at least one lesion = 1.5 cm (long axis) with a ligand uptake above liver level. Exclusion Criteria: - Patients whom are pregnant or breast feeding. - Patients with reproductive potential not implementing adequate contraceptives measures. - Patients with known brain metastases or cranial epidural disease or intracardial metastases. - Patients with concurrent serious (as determined by the Principal Investigator) medical conditions, including, but not limited to, New York Heart Association class III or IV congestive heart failure, history of congenital prolonged QT syndrome, uncontrolled infection, active hepatitis B or C, or other significant co-morbid conditions that in the opinion of the investigator would impair study participation or cooperation. - Patients with urinary tract obstruction or marked hydronephrosis - Less than 4 weeks since last myelosuppressive therapy or other radionuclide therapy. - Concomitant cancer treatments |
Country | Name | City | State |
---|---|---|---|
Netherlands | Radboudumc | Nijmegen | Gelderland |
Lead Sponsor | Collaborator |
---|---|
Radboud University Medical Center | Dutch Cancer Society |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Adverse events measured using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 | Safety | Through study completion, up until 3 years after last patient commences treatment | |
Secondary | Objective response rate (ORR) | Response will be measured according to RECIST version 1.1 | Through study completion, up until 3 years after last patient commences treatment | |
Secondary | Progression free survival (PFS) | PFS will be defined as time from study enrollment until disease progression or death. | Through study completion, up until 3 years after last patient commences treatment | |
Secondary | Overall survival (OS) | OS will be defined as time from study enrollment until date of death of any cause. | Through study completion, up until 3 years after last patient commences treatment | |
Secondary | Duration of response (DoR) | Only patients with complete remission or partial response will be included in the assessment of DoR. DoR is defined as time from study enrollment until disease progression or death | Through study completion, up until 3 years after last patient commences treatment | |
Secondary | Quality of life (QoL) | QoL will be assessed using EORTC QLQ-C30 questionnaire. This is the core questionnaire for assessing health related quality of life of cancer patients participating in clinical trials. It contains 30 items and incorporates a global health status scale, five functional scales, three symptom scales, and several single items assessing additional symptoms. All of the scales and single-item measures range from 0-100. A high score for global health status represents a high QoL, a high score in functional scale represents a high/healthy level of functioning, a high score for a symptom scale/item represents a high level of symptomatology/problems. | Trough study completion, up until 3 years after last patient commences treatment | |
Secondary | Quality of life (QoL) | QoL will be assessed using EORTC QLQ-H&N43 questionnaire. This is an additional questionnaire to assess health related topics relevant for head and neck cancer patients. The module contains 43 questions, all symtom scales or symptom items.All of the scale/item measures range from 0-100. For all scales/items higher scores indicate more problems. | Trough study completion, up until 3 years after last patient commences treatment | |
Secondary | Quality of life (QoL) | QoL will be assessed using performance status scale for head&neck cancer patients (PSS-HN). It contains 3 items, each randing from 0-100. These items are rated by the health professional. A high score indicates a high performance status. | Trough study completion, up until 3 years after last patient commences treatment | |
Secondary | Quality of life (QoL) | QoL will be assessed using pain visual analogue scale (VAS) questionnaire. This include two questions: the average pain during the past week and the worst pain during the past week. Both questions range from 0-100, a higher score indicates more pain. | Trough study completion, up until 3 years after last patient commences treatment | |
Secondary | Dosimetry | Delivered doses will be calculated based on pharmacokinetics in the blood and dosimetry on SPECT/CT imaging. | From start of study till last patient commences last SPECT/CT (7 days after first treatment cycle) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04973683 -
AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer
|
Phase 1 | |
Completed |
NCT01417143 -
Dovitinib in Adenoid Cystic Carcinoma
|
Phase 2 | |
Recruiting |
NCT04140526 -
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05010629 -
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
|
Phase 2 | |
Recruiting |
NCT04801264 -
Diagnosis of Adenoid Cystic Carcinoma on 68Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617
|
Early Phase 1 | |
Completed |
NCT03319641 -
PSMA-PET Imaging for Advanced ACC/SDC
|
N/A | |
Recruiting |
NCT02942693 -
Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma
|
Phase 2 | |
Completed |
NCT00581360 -
Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck
|
Phase 2 | |
Not yet recruiting |
NCT05553782 -
Drug Screening Using Novel IMD in ACC and Salivary Cancers
|
Early Phase 1 | |
Active, not recruiting |
NCT02775370 -
A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck
|
Phase 2 | |
Active, not recruiting |
NCT02780310 -
Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma
|
Phase 2 | |
Completed |
NCT04119453 -
A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)
|
Phase 2 | |
Active, not recruiting |
NCT02098538 -
Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
|
Phase 2 | |
Completed |
NCT01558661 -
Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
|
Phase 2 | |
Completed |
NCT01524692 -
Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma
|
Phase 2 | |
Recruiting |
NCT03556228 -
Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
|
Phase 1 | |
Not yet recruiting |
NCT06462183 -
Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)
|
Phase 1 | |
Recruiting |
NCT01192087 -
Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy
|
Phase 1/Phase 2 | |
Recruiting |
NCT04209660 -
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
|
Phase 2 | |
Recruiting |
NCT05774899 -
CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC
|
Phase 1/Phase 2 |